Navigation Links
FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
Date:11/13/2013

s cause blood flow problems, which can lead to severe pain, irreversible organ damage, and early death.  The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in early 2014. More information can be found on the Company's web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements

Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to the Company's development plans for MST-188 in acute limb ischemia, including its planned phase 2 clinical study in acute limb ischemia, and the potential application of MST-188 in stroke and other indications in which thrombolytic agents are used.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future nonclinical and clinical studies of MST-188 and the risk that MST-188 may not demonstrate adequate safety, efficacy or tolerability in one or more such studies; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," or suspension or termination o
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. European Commission Designates MST-188 As An Orphan Medicinal Product
2. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
3. Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
4. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
5. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
6. Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
7. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
8. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
9. Orphan Drugs for Cancer: R&D and Market 2013-2023
10. Epizyme Receives Orphan Drug Designation for EPZ-5676
11. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  Encision Inc. (PK:ECIA), a medical device company ... burns in minimally invasive surgery, today announced financial results ... 30, 2015. The Company posted quarterly net ... of $213 thousand, or $(0.02) per share. These results ... net loss of $202 thousand, or $(0.02) per share, ...
(Date:8/2/2015)... LONDON , August 3, 2015 ... Dechra Pharmaceuticals PLC ("Dechra" or the "Company") ... share purchase agreement ("SPA") with Mr. Marijan Han ... voting rights) in Genera d.d. ("Genera"), a Croatian listed ... (HRK179.60) per share, which is equivalent to €51.4 million ...
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2
... Immunomedics, Inc. (Nasdaq: IMMU ) , ... to treat cancer and other serious diseases, today ... Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, ... animal models as an effective new therapy. ...
... Fla., Jan. 19 A new approach to unblocking ... down time, lower costs and less risk overall, particularly ... the 21st annual International Symposium on Endovascular Therapy (ISET). ... over bypass surgery to open their blocked arteries. New ...
Cached Medicine Technology:Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 2Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 3Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has ... , The acquisition includes all of IBAM NA’s cyclotron sites and research and development ... robust regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” ...
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania wanted to have ... diabetes after many years of suffering and using medications with strong side effects. This ... ask for extra time off or wait longer hours in the waiting rooms. Instead, ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... provider of medical information, risk management and investigative services, has introduced a ... toward focused, expert information solutions that improve business outcomes for its customers. ...
(Date:8/3/2015)... Louisville, KY (PRWEB) , ... August 03, 2015 , ... ... suffer from lower back pain at least once in their lives. Often time, low ... bulges. Until recently, disc herniations could only be managed clinically with powerful pain medication ...
(Date:8/2/2015)... Francisco, CA (PRWEB) , ... August 03, 2015 , ... For many “would be” ... do I get help” or “I can’t afford to start a business.” Neither needs be ... has the right and theoretical opportunity to start a business and be successful. The risks ...
Breaking Medicine News(10 mins):Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5
... Sept. 10 Birner Dental Management Services, Inc. (Nasdaq: ... dental practices announced its regular quarterly dividend. The Company,s ... cents per share of common stock. The dividend is payable ... , Birner Dental Management Services, Inc. acquires, develops, ...
... , MENLO PARK, Calif., Sept. 10 ... today announced that new research on nicotine dependence is featured ... and Endophenotypes: Foundations for Genetic Studies of Nicotine Use ... Center for Health Sciences, was the senior scientific editor of ...
... , QUINCY, Mass., Sept. 10 ... flu shots as part of its Health & Wellness initiative in ... during the cough and cold season . This year, Stop & ... Stop & Shop card holders in the pharmacy department beginning Friday, ...
... rare and dangerous disease, new laboratory research at The University ... lead researchers toward clues in more common diseases, including highly ... in the Sept. 11 issue of the journal Molecular ... damage sites is controlled by replication in both FA and ...
... 10, 2009 When a terrorist bomb explodes, a ... region, or wildfires ravage homes and businesses, plastic surgeons ... But they should be, UT Southwestern Medical ... September issue of Plastic and Reconstructive Surgery . ...
... RESTON, Va.SNM applauds the U.S. Food and Drug Administration,s ... Zevalin, as a front-line treatment of non-Hodgkin,s lymphoma ... with non-Hodgkin,s lymphoma," said Michael M. Graham, M.D., Ph.D., ... the University of Iowa Carver College of Medicine. "We,ve ...
Cached Medicine News:Health News:SRI International's Research on Nicotine Use and Dependence Featured in the National Cancer Institute's Tobacco Control Monograph Series 2Health News:SRI International's Research on Nicotine Use and Dependence Featured in the National Cancer Institute's Tobacco Control Monograph Series 3Health News:Stop & Shop To Offer Seasonal Flu Shots 2Health News:Stop & Shop To Offer Seasonal Flu Shots 3Health News:Replication at DNA damage sites highlights Fanconi anemia and breast cancer proteins 2Health News:Plastic surgeons should be part of disaster relief planning, response 2Health News:Plastic surgeons should be part of disaster relief planning, response 3Health News:SNM applauds FDA's decision to approve Zevalin 2
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
... includes fixed-volume, adjustable-volume, and multichannel models ... Research pro Pipette. Designed with a ... pipettes have earned a worldwide reputation ... with original Eppendorf pipette tips, they ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
Medicine Products: